Skip to Main Content

Automated detection and quantification of ARIA-H and ARIA-E

Our AI software enables consistent, longitudinal tracking of patients receiving anti-amyloid therapies. Offering precise therapeutic surveillance for anti-amyloid medications, it improves patient monitoring and outcomes.

Research use only – not yet FDA cleared.

AI-Assisted Monitoring of Anti-Amyloid Immunotherapies for Alzheimer's Disease.

Comprehensive FLAIR lesion segmentation and identification – within minutes. With capabilities including precise therapeutic surveillance (including detection and tracking of lesion count, max diameter, and volume) for patients on anti-amyloid medications, NeuroQuant ARIA is designed to improve patient monitoring and outcomes.

Benefits

ARIA-E and ARIA-H

Precise monitoring of ARIA-H and ARIA-E lesion counts

OEM protocol standardization

To ensure reproducible outcomes and accuracy over time

1200 clinical sites

Extensive network of locations supports convenient patient access

Quantitative lesion detection

Use T2*GRE and FLAIR images to extract lesion quantitative measures

Longitudinal disease tracking

Monitor lesion counts and maximum diameters over time, with comparisons to baseline and prior timepoints

NeuroQuant® ARIA reports

Reports that assist in clinical decision-making by better characterizing ARIA, quantitating its occurrence, and assessing rate of change over time.

Sample NeuroQuant® ARIA reports

NeuroQuant ARIA-H report provides automated microhemorrhage count and superficial siderosis area detection for patients receiving anti-amyloid therapies.

NeuroQuant ARIA-E Report provides detection and tracking of lesion count, max diameter, and volume for patients receiving anti-amyloid therapies.